Related Experiment Video
Updated: Aug 19, 2026
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
[A clinical study on adoptive immunotherapy of bone metastatic neoplasm with tumor infiltrating lymphocytes]
1Department of Orthopedic Surgery, Second Affiliated Hospital Suzhou Medical College.
In order to establish a more efficient and less toxic approach than lymphokine activated killer (LAK) cell in adoptive immunotherapy (AIT), tumor infiltrating lymphocytes (TILs) were isolated from operation and biopsy samples of 10 patients with bone metastatic tumor during 1990 approximately 1992. TILs activated and expanded in vitro were adoptively transferred to patients with bone metastatic lesions. Complete response in 1, partial response in 2, minor response in 3 and nonresponse in 4 patients with TILs immunotherapy were observed. The effective rate was 30%, P > 0.01. The results of this preliminary study indicate that adoptive immunotherapy with large number of TILs is an encouraging approach in the treatment of advanced neoplasm with bone metastasis.
In order to establish a more efficient and less toxic approach than lymphokine activated killer (LAK) cell in adoptive immunotherapy (AIT), tumor infiltrating lymphocytes (TILs) were isolated from operation and biopsy samples of 10 patients with bone metastatic tumor during 1990 approximately 1992. TILs activated and expanded in vitro were adoptively transferred to patients with bone metastatic lesions. Complete response in 1, partial response in 2, minor response in 3 and nonresponse in 4 patients with TILs immunotherapy were observed. The effective rate was 30%, P > 0.01. The results of this preliminary study indicate that adoptive immunotherapy with large number of TILs is an encouraging approach in the treatment of advanced neoplasm with bone metastasis.
